Skip to main content
Erschienen in: International Cancer Conference Journal 1/2012

01.03.2012 | Case report

Development of retinoic acid syndrome during leukopenia

verfasst von: Katsuki Sugiyama, Noriko Usui, Nobuaki Dobashi, Shingo Yano, Yutaka Takei, Shinobu Takahara, Takeshi Saito, Keisuke Aiba

Erschienen in: International Cancer Conference Journal | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

We present a case involving a 53-year-old male with acute promyelocytic leukemia who developed retinoic acid syndrome (RAS) during leukopenia. He received all-trans retinoic acid (ATRA) therapy at a dose of 90 mg/day (45 mg/m2). On day 17, his fever increased to 38.1°C. As pain developed in his left ankle on day 19, ATRA was discontinued on day 20 because of the suspicion of an adverse reaction to the therapy such as RAS. On day 28, his fever increased markedly, and respiratory distress and bilateral pleural effusion developed. Although his maximum leukocyte count during the course of the condition was low (3,800/μl), steroid pulse therapy was started on day 32. Thereafter, these symptoms improved dramatically. Based on the clinical manifestations observed and the patient’s complete response to steroid pulse therapy, RAS was considered to have developed in the present case. RAS is associated with the development of hyperleukocytosis in most patients, but a few patients with normal leukocyte counts have developed the syndrome. As RAS is a fatal complication of ATRA therapy, early diagnosis and treatment are very important. The present case emphasizes the view that when administering ATRA, RAS should be kept in mind at all times.
Literatur
1.
Zurück zum Zitat Tallman MS, Nabhan C, Feusner JH et al (2002) Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 99:759–767PubMedCrossRef Tallman MS, Nabhan C, Feusner JH et al (2002) Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 99:759–767PubMedCrossRef
2.
Zurück zum Zitat Frankel SR, Eardley A, Lauwers G et al (1992) The ‘retinoic acid syndrome’ in acute promyelocytic leukemia. Ann Intern Med 117:292–296PubMed Frankel SR, Eardley A, Lauwers G et al (1992) The ‘retinoic acid syndrome’ in acute promyelocytic leukemia. Ann Intern Med 117:292–296PubMed
3.
Zurück zum Zitat Fenaux P, Chomienne C, Degos L (2001) All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Semin Hematol 38:13–25PubMedCrossRef Fenaux P, Chomienne C, Degos L (2001) All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Semin Hematol 38:13–25PubMedCrossRef
4.
Zurück zum Zitat Tallman MS, Andersen JW, Schiffer CA et al (2000) Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood 95:90–95PubMed Tallman MS, Andersen JW, Schiffer CA et al (2000) Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood 95:90–95PubMed
5.
Zurück zum Zitat Vahdat L, Maslak P, Miller WH Jr et al (1994) Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PML/RAR-α isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 84:3843–3849PubMed Vahdat L, Maslak P, Miller WH Jr et al (1994) Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PML/RAR-α isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 84:3843–3849PubMed
6.
Zurück zum Zitat Fenaux P, Botton SD (1998) Retinoic acid syndrome, recognition, prevention and management. Drug Saf 18:273–279PubMedCrossRef Fenaux P, Botton SD (1998) Retinoic acid syndrome, recognition, prevention and management. Drug Saf 18:273–279PubMedCrossRef
7.
Zurück zum Zitat Montesinos P, Bergua JM, Vellenga E et al (2009) Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 113:775–783PubMedCrossRef Montesinos P, Bergua JM, Vellenga E et al (2009) Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 113:775–783PubMedCrossRef
8.
Zurück zum Zitat Ohno R, Asou N, Ohnishi K (2003) Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. Leukemia 17:1454–1463PubMedCrossRef Ohno R, Asou N, Ohnishi K (2003) Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. Leukemia 17:1454–1463PubMedCrossRef
9.
Zurück zum Zitat De Botton S, Chevret S, Coiteux V et al (2003) Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93trial. Leukemia 17:339–342PubMedCrossRef De Botton S, Chevret S, Coiteux V et al (2003) Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93trial. Leukemia 17:339–342PubMedCrossRef
Metadaten
Titel
Development of retinoic acid syndrome during leukopenia
verfasst von
Katsuki Sugiyama
Noriko Usui
Nobuaki Dobashi
Shingo Yano
Yutaka Takei
Shinobu Takahara
Takeshi Saito
Keisuke Aiba
Publikationsdatum
01.03.2012
Verlag
Springer Japan
Erschienen in
International Cancer Conference Journal / Ausgabe 1/2012
Elektronische ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-011-0006-x

Weitere Artikel der Ausgabe 1/2012

International Cancer Conference Journal 1/2012 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.